Icos Corporation

Array Biopharma Inc.

Pfizer Corporation

Bradley Jon Newhouse

John Joseph Gaudino

Kerry W Fowler

Edward A Kesicki

Laurence Edward Burgess

Amy Oliver

Joshua O Odingo

Timothy J Martins

Zachary S Jones

Stephen T Schlachter

Ellen Ruth Laird

Spencer Phillip Pajk

Erik James Hicken

Adam Wade Cook

Li Ren

David A Moreno

Andrew T Metcalf

Dean Russell Kahn

Brett Joseph Prigaro

Patrick Michael Barbour

Eugene Tarlton

Stephen T Schlacter

Katie Keaton Brown

Nicholas Charles Lazzara

Mark Laurence Boys

Bryan Daniel Ellis

Russell Andrew Shelp

Rachel Zoe Rosen

Andrew Terrance Metcalf

David Austin Moreno

This invention relates to compounds of Formula (I): and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein A, L, R, R, R, R, and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts, and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

HER2 mutation inhibitors

This invention relates to compounds of Formula (I): and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein L, L, R, R, Rand n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors

Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X, R, R, R, R, Rand Rare as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.

Compounds for the treatment of BRAF-associated diseases and disorders

Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.

Cyclic AMP-specific phosphodiesterase inhibitors

Cyclic AMP-specific phosphodie sterase inhibitors

Growing community of inventors

Broomfield, CO, United States of America

Bradley Jon Newhouse